{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:41:43Z","timestamp":1770043303895,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s11060-020-03404-z","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T10:02:55Z","timestamp":1579773775000},"page":"109-116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients"],"prefix":"10.1007","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3972-7544","authenticated-orcid":false,"given":"Bruno","family":"Carvalho","sequence":"first","affiliation":[]},{"given":"Rafaela Gon\u00e7alves","family":"Lopes","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Linhares","sequence":"additional","affiliation":[]},{"given":"Andreia","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Cl\u00e1udia","family":"Caeiro","sequence":"additional","affiliation":[]},{"given":"Ana Catarina","family":"Fernandes","sequence":"additional","affiliation":[]},{"given":"Nuno","family":"Tavares","sequence":"additional","affiliation":[]},{"given":"L\u00edgia","family":"Os\u00f3rio","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Vaz","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,1,23]]},"reference":[{"issue":"8","key":"3404_CR1","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/cncr.26494","volume":"118","author":"AS Darefsky","year":"2012","unstructured":"Darefsky AS, King JT Jr, Dubrow R (2012) Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries. Cancer 118(8):2163\u20132172. https:\/\/doi.org\/10.1002\/cncr.26494","journal-title":"Cancer"},{"key":"3404_CR2","unstructured":"Stupp RJNEJM (2005) European Organisation for Research and Treatment of Cancer brain tumor and radiotherapy groups; National Cancer Institute of Canada clinical trials group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma 352:987\u2013996"},{"issue":"11","key":"3404_CR3","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","volume":"14","author":"MH Cohen","year":"2009","unstructured":"Cohen MH, Shen YL, Keegan P, Pazdur R (2009) FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14(11):1131\u20131138. https:\/\/doi.org\/10.1634\/theoncologist.2009-0121","journal-title":"Oncologist"},{"issue":"28","key":"3404_CR4","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733\u20134740. https:\/\/doi.org\/10.1200\/JCO.2008.19.8721","journal-title":"J Clin Oncol"},{"issue":"8","key":"3404_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709\u2013722. https:\/\/doi.org\/10.1056\/NEJMoa1308345","journal-title":"N Engl J Med"},{"issue":"8","key":"3404_CR6","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699\u2013708. https:\/\/doi.org\/10.1056\/NEJMoa1308573","journal-title":"N Engl J Med"},{"key":"3404_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/MCG.0b013e3182a8804c","volume":"48","author":"Leila Khoja","year":"2014","unstructured":"Khoja Leila, Kumaran G, Zee YK, Murukesh Nishanth, Swindell Ric, Saunders MP, Clamp AR, Valle JW, Jayson GWGC, Hasan J (2014) Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer. J Clin Gastroenterol 48:4","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"3404_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/CAD.0b013e32835aa5fd","volume":"24","author":"G Lombardi","year":"2013","unstructured":"Lombardi G, Zustovich F, Farina P, Fiduccia P, Della Puppa A, Polo V, Bertorelle R, Gardiman MP, Banzato A, Ciccarino P, Denaro L, Zagonel V (2013) Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature. Anticancer Drugs 24(1):90\u201397. https:\/\/doi.org\/10.1097\/CAD.0b013e32835aa5fd","journal-title":"Anticancer Drugs"},{"issue":"4","key":"3404_CR9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/bjc.2011.2","volume":"104","author":"P Osterlund","year":"2011","unstructured":"Osterlund P, Soveri LM, Isoniemi H, Poussa T, Alanko T, Bono P (2011) Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer 104(4):599\u2013604. https:\/\/doi.org\/10.1038\/bjc.2011.2","journal-title":"Br J Cancer"},{"issue":"9","key":"3404_CR10","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1002\/cncr.29234","volume":"121","author":"J Zhong","year":"2015","unstructured":"Zhong J, Ali AN, Voloschin AD, Liu Y, Curran WJ Jr, Crocker IR, Shu HK (2015) Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab. Cancer 121(9):1456\u20131462. https:\/\/doi.org\/10.1002\/cncr.29234","journal-title":"Cancer"},{"key":"3404_CR11","unstructured":"Institute NC (2017) Common terminology criteria for adverse events, version 5.0. 28\/03\/2019 edn. National Cancer Institute, National Institutes of Health, Department of Health and Human Services"},{"issue":"6","key":"3404_CR12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrclinonc.2009.63","volume":"6","author":"RK Jain","year":"2009","unstructured":"Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6(6):327","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"3404_CR13","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1634\/theoncologist.2010-0002","volume":"16","author":"O Mir","year":"2011","unstructured":"Mir O, Coriat R, Cabanes L, Ropert S, Billemont B, Alexandre J, Durand JP, Treluyer JM, Knebelmann B, Goldwasser F (2011) An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist 16(9):1325\u20131332. https:\/\/doi.org\/10.1634\/theoncologist.2010-0002","journal-title":"Oncologist"},{"issue":"1","key":"3404_CR14","first-page":"227","volume":"34","author":"SP Gampenrieder","year":"2014","unstructured":"Gampenrieder SP, Romeder F, Muss C, Pircher M, Ressler S, Rinnerthaler G, Bartsch R, Sattlberger C, Mlineritsch B, Greil R (2014) Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis. Anticancer Res 34(1):227\u2013233","journal-title":"Anticancer Res"},{"issue":"2","key":"3404_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/annonc\/mdn637","volume":"20","author":"M Scartozzi","year":"2009","unstructured":"Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S (2009) Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 20(2):227\u2013230. https:\/\/doi.org\/10.1093\/annonc\/mdn637","journal-title":"Ann Oncol"},{"issue":"20","key":"3404_CR16","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","volume":"377","author":"W Wick","year":"2017","unstructured":"Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Stupp R, Fabbro M, Le Rhun E, Dubois F, Weller M, von Deimling A, Golfinopoulos V, Bromberg JC, Platten M, Klein M, van den Bent MJ (2017) Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 377(20):1954\u20131963. https:\/\/doi.org\/10.1056\/NEJMoa1707358","journal-title":"N Engl J Med"},{"issue":"17","key":"3404_CR17","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1200\/JCO.2009.26.3988","volume":"28","author":"TT Batchelor","year":"2010","unstructured":"Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK (2010) Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28(17):2817\u20132823. https:\/\/doi.org\/10.1200\/JCO.2009.26.3988","journal-title":"J Clin Oncol"},{"issue":"5","key":"3404_CR18","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","volume":"27","author":"TN Kreisl","year":"2009","unstructured":"Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740\u2013745. https:\/\/doi.org\/10.1200\/JCO.2008.16.3055","journal-title":"J Clin Oncol"},{"issue":"1","key":"3404_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11060-010-0217-6","volume":"101","author":"DA Reardon","year":"2011","unstructured":"Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, Marcello J, Herndon JE 2nd, McLendon RE, Janney D, Friedman AH, Bigner DD, Friedman HS (2011) Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 101(1):57\u201366. https:\/\/doi.org\/10.1007\/s11060-010-0217-6","journal-title":"J Neurooncol"},{"issue":"1","key":"3404_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s11060-009-0003-5","volume":"97","author":"A Wick","year":"2010","unstructured":"Wick A, Schafer N, Dorner N, Schemmer D, Platten M, Bendszus M, Wick W (2010) Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome. J Neurooncol 97(1):157\u2013158. https:\/\/doi.org\/10.1007\/s11060-009-0003-5","journal-title":"J Neurooncol"},{"key":"3404_CR21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.2021","author":"CS Nangia","year":"2011","unstructured":"Nangia CS, Wang D, Scarpace L, Schultz L, Khanshour A, Mikkelsen T (2011) The role of the development of hypertension or proteinuria in predicting outcome with the use of bevacizumab for patients with glioblastoma multiforme. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2011.29.15_suppl.2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"3404_CR22","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/annonc\/mdm550","volume":"19","author":"JJ Mourad","year":"2008","unstructured":"Mourad JJ, des Guetz G, Debbabi H, Levy BI (2008) Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 19(5):927\u2013934. https:\/\/doi.org\/10.1093\/annonc\/mdm550","journal-title":"Ann Oncol"},{"issue":"9","key":"3404_CR23","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","volume":"15","author":"W Taal","year":"2014","unstructured":"Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15(9):943\u2013953. https:\/\/doi.org\/10.1016\/S1470-2045(14)70314-6","journal-title":"Lancet Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-020-03404-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-020-03404-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-020-03404-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:44:09Z","timestamp":1611276249000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-020-03404-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,23]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["3404"],"URL":"https:\/\/doi.org\/10.1007\/s11060-020-03404-z","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,23]]},"assertion":[{"value":"16 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}